The product (RJ-LC-07-48) is potent against drug-resistant non-small-cell lung cancer (NSCLC) cells by interaction with the minichromosomal maintenance protein MCM2, disrupting the formation of the MCM complex that is required for the initiation of DNA replication [73]. Here, MCM2 is linked to non-small cell lung carcinoma.